RepublicanBill · S. 3510· Senate(119-S-3510)

Biosimilar Inspection Modernization Act of 2025

Rep. Budd
Age: 55 years
North Carolina
Introduced
12/16/2025
Last activity
12/16/2025 — Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsored by
Ted Budd
Cosponsors
Republican - 0Democrat - 1
Health
  1. Introduced
  2. In Committee

What this bill would do

This bill is known as the Biosimilar Inspection Modernization Act of 2025. It aims to improve how the Food and Drug Administration inspects places that make biosimilar biological products. The bill requires the Secretary of Health and Human Services to hold a public meeting and issue a report on mutual recognition agreements. It also directs the Secretary to update inspection processes and tools to use a risk-based approach. Finally, the bill requires the creation of a strategic plan to address domestic inspection challenges within one year of enactment.

Yes· 3 of 10

  • Does this lower the price of prescription medicines?+4

    Streamlining the regulatory inspection process for biosimilars can help foster competition and potentially lower prescription drug costs for consumers.

  • Would business owners be better off under this?+3

    Biosimilar application sponsors and pharmaceutical establishments benefit from clearer inspection frameworks, remote assessment tools, and better communication.

  • Does this make health care easier to get in general?+3

    Modernizing biosimilar inspections helps ensure timely review and availability of important biological products for patients.

The opposite

No question was scored the opposite.